A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery

The overall objective of this double blinded, randomized controlled trial (RCT) is to compare specific outcomes of three medications (Dexmedetomidine, Nicardipine, and Labetalol) which are routinely used to lower blood pressure used during general anesthesia for orthognathic (jaw) surgery. The outcome measures for the study will be surgical field visibility, estimated blood loss, hemodynamic parameters, operation time, and adverse events.
The specific objectives of this study are to compare:
1. Dexmedetomidine, Nicardipine, and Labetalol's effect on the quality of the surgical field. (Primary Outcome)
2. Dexmedetomidine, Nicardipine, and Labetalol's effect on estimated blood loss.
3. Dexmedetomidine, Nicardipine, and Labetalol's effect on hemodynamic parameters including systolic blood pressure, mean arterial pressure, and heart rate.
4. Dexmedetomidine, Nicardipine, and Labetalol's effect on operation time.
5. Dexmedetomidine, Nicardipine, and Labetalol's effect on adverse events.
The investigators will evaluate healthy adult male and female patients who require jaw surgery at Boston Medical Center. The anticipated 90 participants will be randomized into three groups: ) A Labetalol group in which the patients receive hypotensive anesthesia with the aid of labetalol, 2) A Nicardipine group in which the patients receive hypotensive anesthesia with the aid of nicardipine, and 3) A Dexmedetomidine group in which the patients receive hypotensive anesthesia with the aid of dexmedetomidine.
The time it will take for each individual participant ranges from 1-3 months. This time includes the pre-operative visit, the surgical procedure, a 1-week post-operation visit, and then followed for 30 days post-operatively after which the patient's participation in the study will conclude.

开始日期2025-01-01

申办/合作机构

Boston Medical Center

NCT06677970 / Not yet recruiting临床3期IIT

Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2)

Though intravenous thrombolysis has been shown to improve symptoms in acute ischemic stroke patients, the recanalization rate remains low (22.6%) and only around 30% of patients benefit from the treatment. Recently, endovascular thrombectomy using stent retrievers or catheters has proven to be more effective, with a success rate of nearly 80%. However, only 50% of patients experience clinical improvement, highlighting the need for new treatment strategies to enhance outcomes. Current guidelines recommend maintaining systolic blood pressure (BP) below 180 mmHg after thrombectomy, but there is a lack of evidence regarding optimal blood pressure management post-reperfusion.
Four randomized clinical trials, including the OPTIMAL-BP trial, have examined blood pressure control following thrombectomy. Meta-analyses showed that intensive BP lowering did not reduce symptomatic hemorrhage and was associated with worse functional outcomes at 3 months. Specifically, lowering BP too aggressively after successful reperfusion could worsen outcomes by reducing perfusion to the ischemic penumbra. Therefore, this study will investigate whether a more targeted blood pressure elevation strategy could improve patient prognosis compared to standard BP control in those with post-thrombectomy systolic BP below 140 mmHg.
This is a prospective, randomized, open-label trial with blinded endpoint assessment (PROBE) design, aimed at comparing intensive and standard BP control strategies in acute ischemic stroke patients. Participants will be randomized 1:1 into either an intensive BP control group (targeting a 20% systolic BP increase, capped at 180 mmHg) or a standard BP control group (systolic BP below 180 mmHg).

开始日期2024-12-01

申办/合作机构

Yonsei University

NCT05551104 / Recruiting临床3期IIT

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)

The purpose of this investigator-initiated randomized control trial is to determine whether oral Nifedipine versus oral Labetalol is superior in controlling high blood pressures in the postpartum period.

开始日期2024-12-01

申办/合作机构

Loma Linda University

100 项与盐酸拉贝洛尔相关的临床结果

登录后查看更多信息

100 项与盐酸拉贝洛尔相关的转化医学

登录后查看更多信息

100 项与盐酸拉贝洛尔相关的专利（医药）

登录后查看更多信息

2,334

项与盐酸拉贝洛尔相关的文献（医药）

2024-12-01·Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health

Optimal treatment for women with acute hypertension in pregnancy; a randomized trial comparing intravenous labetalol versus nicardipine

Article

作者: de Groot, Christianne J M ; Bij de Weg, Jeske M ; bij de Weg, Jeske M. ; de Groot, Christianne J.M. ; Ganzevoort, Wessel ; de Boer, Marjon A. ; Willem Mol, Ben ; Hermes, Wietske ; de Boer, Marjon A ; van Bel, Frank ; Gravesteijn, Benjamin Y ; Gravesteijn, Benjamin Y.

OBJECTIVES:

Blood pressure control in severe hypertension of pregnancy is crucial for mother and neonate. In absence of evidence, guidelines recommend either intravenous labetalol or nicardipine. We compared the effectiveness and safety of these two drugs in women with severe hypertension in pregnancy.

STUDY DESIGN:

We performed an open label randomized controlled trial. Women with a singleton pregnancy complicated by severe hypertension (systolic ≥ 160 mmHg and/or diastolic ≥ 110 mmHg) requiring intravenous antihypertensive treatment were randomized to intravenous labetalol or intravenous nicardipine. The primary outcome was a composite adverse neonatal outcome defined as severe Respiratory Distress Syndrome (RDS), Broncho Pulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH) IIB or worse, Necrotizing Enterocolitis (NEC), or perinatal death defined as fetal death or neonatal death before discharge from the neonatal intensive care unit (NICU). Based on a power analysis, we estimated that 472 women (236 per group) needed to be included to detect a difference of 15% in the primary outcome with 90% power. The study was halted prematurely at 30 inclusions because of slow recruitment and trial fatigue.

RESULTS:

Between August 2018 and April 2022, we randomized 30 women of which 16 were allocated to intravenous nicardipine and 14 to intravenous labetalol. The composite adverse neonatal outcome was not significantly different between the two groups (25 % versus 43 % OR 0.28 (95 % CI 0.05-1.43), p = 0.12)). Respiratory distress syndrome occurred more often in the labetalol group than in the nicardipine group (42.9 % versus 12.5 %). Neonatal hypoglycemia occurred more often in the nicardipine group than in the labetalol group (31 % versus 7 %). Time until blood pressure control was faster in women treated with nicardipine than in women treated with labetalol (45 (15-150 min vs. 120 (60-127,5) min).

CONCLUSION:

In our prematurely halted small RCT, we were unable to provide evidence for the optimal choice of treatment for severe hypertension to improve neonatal outcome and/or to obtain faster blood pressure control. Differences in Respiratory distress syndrome and neonatal hypoglycemia between the groups might be the result of coincidental finding due to the small groups included in the study. A larger randomized trial would be needed to determine the safest and most efficacious (intravenous) therapy for severe hypertension in pregnancy. This study emphasizes the challenges of conducting a RCT for the optimal treatment for these women.

2024-12-01·European Journal of Obstetrics & Gynecology and Reproductive Biology

Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trials

Review

作者: Kojima, Giovana Schlichta Adriano ; Faria, Hilária Saugo ; de Azevedo, Benjamim Barbosa ; Simoni, Gabriel Henrique ; da Silva Júnior, Arlindo Bispo ; Bendaham, Lucas Cael Azevedo Ramos ; de Macedo Lins, Cynthia Dantas ; Ribeiro, Bianca Leal ; de Abreu, Victoria Städler ; de Araújo Melo, Keliany Carla Duarte ; Soares, Victor Gonçalves ; Gonçalves, Ocílio Ribeiro ; de Araújo Melo, Keliany C. Duarte

INTRODUCTION:

Hypertensive disorders during pregnancy elevate the likelihood of unfavorable outcomes for both mother and fetus. In cases of acute hypertension, several pharmacological interventions are available to lower blood pressure, such as hydralazine, a direct arteriolar vasodilator, and labetalol, a combined alpha and beta-blocker.

OBJECTIVES:

This systematic review and meta-analysis of randomized controlled trials (RCTs) aims to compare the efficacy and safety of intravenous labetalol and intravenous hydralazine for acute hypertensive disorders during pregnancy.

METHODS:

We systematically searched PubMed, Embase and Cochrane for studies comparing labetalol versus hydralazine in pregnant patients. The primary outcomes were median arterial blood pressure (MABP), diastolic blood pressure (DBP) and systolic blood pressure (SBP). We performed statistical analyses using R 4.1.1. Heterogeneity was examined with the Cochran Q test and I² statistics. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI), were computed with a random-effects model.

RESULTS:

Nineteen RCTs were included in this meta-analysis, comprising 2,261 patients. Among them, 1,131 (50 %) received treatment with labetalol. There was no statistically significant difference between groups in terms of SBP (MD -1.74; 95 % CI -6.72 to 3.23; p = 0.49; I² = 93 %), MABP (MD -0.72; 95 % CI -2.34 to 0.90; p = 0.39; I² = 0 %), DBP (MD 0.25; 95 % CI -4.72 to 5.21; p = 0.92; I² = 96 %), tachycardia (RR 0.42; 95 % CI 0.15 to 1.18; p = 0.099; I² = 41 %), and placenta abruption (RR 0.42; 95 % CI 0.15 to 1.16; p = 0.093; I² = 0 %). However, labetalol significantly reduced maternal hypotension (RR 0.26; 95 % CI 0.21 to 0.33; p < 0.001; I² = 41 %) compared with hydralazine.

CONCLUSION:

This systematic review and meta-analysis of RCTs found that labetalol and hydralazine were efficient for hypertension disorders in pregnancy. However, labetalol reduced the incidence of maternal hypotension.

2024-12-01·European journal of obstetrics & gynecology and reproductive biology: X

A rapid diagnostic technique based on metabolomics to differentiate between preeclampsia (PE) and chronic kidney disease (CKD) using maternal urine

Article

作者: Zhuang, Xu ; Lv, Xin ; Gao, Boyan ; Hou, Jingli

Similar clinical manifestations between preeclampsia and chronic kidney diseases can lead to potential misdiagnosis. Therefore, it is crucial to investigate effective diagnostic approaches that can reduce misdiagnosis and ensure the well-being of pregnant women. In this study, urine samples collected from 44 individuals with preeclampsia, 37 individuals with chronic kidney disease, and 37 healthy pregnant women were analyzed using metabolomic and proteomic strategies to distinguish between these two diseases. A total of 15 small molecules were tentatively identified as biomarkers to differentiate these two diseases, including potential internally exposed drugs and their metabolites like labetalol and SN-38, metabolites of exogenous substances like 3-phenylpropyl glucosinolate, and endogenous substances related to metabolism such as isoglobotriaose and chitobiose. Metabolic differences between preeclampsia from healthy pregnant women, as well as the differences between chronic kidney disease and healthy pregnant women were also investigated. Major mechanistic pathways were investigated based on the combination of metabolomic and proteomic, amino acid metabolisms and folate metabolism play key roles in distinguishing preeclampsia and chronic kidney disease. Two patients who were initially diagnosed with chronic kidney disease were found to have a closer association with preeclampsia following metabolomic analysis. Subsequent clinical symptoms and manifestations further supported the diagnosis of preeclampsia, and one of patient's pregnancy was ultimately terminated due to severe preeclampsia. Results of this study contribute to a better understanding of the pathogenesis and clinical diagnosis of preeclampsia, offering insights that could potentially improve future diagnostic and management approaches.

项与盐酸拉贝洛尔相关的新闻（医药）

2024-09-03

·Pharmaceutical Technology

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

At the ESC Congress, Dr. Milton Packer highlighted recent research into beta blocker treatment for myocardial infarction. Credit: luchschenF via Shutterstock. A shift in the beta-blocker treatment paradigm has arrived with the changing myocardial infarction treatment landscape, said a researcher at the European Society of Cardiology (ESC) Congress, held from 31 August to 2 September. Over the past 40 years, the research space has operated on an understanding that immediate inhibition by beta-blockers reduces left ventricular rupture, and further myocardial infarction , said Dr. Milton Packer, distinguished scholar in cardiovascular science at Baylor University Medical Center, Dallas. Additionally, the belief was that delayed long-term blockade can lead to left ventricular dysfunction, he said. Beta-blockers are a class of drugs that act by inhibiting the actions of hormones such as adrenaline to slow down the heart. Commonly used beta blockers include Abbott ’s Tenormin (atenolol), MSD’s Cardicor (bisoprolol), and GSK ’s Trandate (labetalol). However, Packer explained that the beta blocker response has changed as percutaneous interventions, reperfusion therapies, antiplatelet drugs and more have entered the treatment landscape for myocardial infarction. At the ongoing ESC Congress talk titled “Should we give beta blockers post-myocardial infarction?” Packer said that questions have been raised surrounding the use of the drugs in patients with myocardial infarction and preserved ejection fraction, referencing the Phase IIII REDUCE-AMI study (NCT03278509). See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication REDUCE-AMI, which was funded by the Swedish Research Council, tested the use of beta-blockers after myocardial infarction and preserved ejection fraction. The study found that for patients with acute myocardial infarction who underwent early coronary angiography and had preserved left ventricular ejection fraction, long-term beta-blocker treatment did not lower the risk of death from any cause or new myocardial infarctions compared to no beta-blocker use. Despite the conclusion of the REDUCE-AMI study, Packer highlighted the fact that researchers have only investigated and proven the effectiveness of non-selective beta blockers in post-myocardial infarction trials, so further research is required. He added that physicians will have to take into account the degree of beta-blockade in future treatment regimens.

疫苗临床3期上市批准临床结果

2024-07-11

·梅斯医学

OCC-WCC 2024 | 专访余静教授：探索性别差异：精准化高血压管理中的女性焦点

随着科学家们对高血压研究的不断精准化，不同性别之间的血压管理差异已成为热议话题。女性一生中高血压的管理是一个动态的过程，例如月经初潮、妊娠期、绝经期以及老年期，女性血压变化都有着不同的特点。因此，女性更需要加倍关注高血压的防控和治疗，以确保身心健康和生活质量。近期，在第十八届东方心脏病学会议（OCC2024）和世界心脏病学大会（WCC2024）上，来自兰州大学第二医院的余静教授以《女性一生中的高血压管理》为题，从女性患者一生血压变化轨迹、女性不同时期高血压的特点以及女性高血压的管理三个方面进行了精彩的讲解。梅斯医学紧跟学术前沿，特邀余静教授全面解读女性在不同的生理阶段高血压的发病机制和管理策略的差异。梅斯医学：在女性的不同生理阶段（如青春期、妊娠期、更年期等），高血压的发病机制和管理策略有哪些差异？余静教授：由于女性的血压受年龄、月经周期、生育及绝经后性激素的变化，还有疾病过程和特殊药物等多方面影响，比男性高血压更为复杂。从生理规律来看，在成年阶段，健康女性的血压水平普遍低于同龄男性，直至绝经后逆转。年轻女性的高血压发病率较低，但随年龄增长，到了绝经后性别差异逐渐缩小，特别是进入老年期，女性高血压的患病率超越男性。青春期的高血压可能与遗传背景紧密相关，同时也受到生活方式及激素水平的影响，如代谢异常、库欣综合征、大动脉炎及多囊卵巢综合症等疾病，以及特定药物（如避孕药）的使用，这些原因引起的高血压更易发生于青少年女性。妊娠期高血压的表现形式多样，包括妊娠期高血压、子痫前期和子痫等，对母婴健康构成威胁。此时的管理需遵循特定指南，强调非药物干预如生活方式调整，而在药物治疗上，需谨慎选择，如拉贝洛尔、甲基多巴和硝苯地平等，避免使用RAAS抑制剂。绝经后，女性高血压管理需考虑激素变化带来的新挑战。尽管多中心研究有限，但现有证据支持RAAS抑制剂在保护绝经后女性靶器官免受高血压损害。我们兰州大学第二医院开展的一项单中心小样本研究同样证实了RAAS抑制剂比其他类型降压药物能更好的保护绝经后女性靶器官的损害。近年来，ARNI类药物的引入为中国高血压患者带来了新的治疗选择，不仅有效降压，还表现出对心脏、肾脏等靶器官的显著保护作用，他们的团队也做了对绝经后女性群体心肾保护的探索。针对女性在各个生理阶段的高血压管理，尽管研究证据尚不充分，但已有的研究表明，RAAS抑制剂（包括ACEI、ARB和ARNI）在靶器官保护方面具有潜在优势。因此，针对女性高血压的治疗应更注重个体化，结合各阶段特点，不仅关注血压控制，还需重视靶器官保护，以预防心脑肾等重要器官的损害。梅斯医学：对于有家族高血压病史的女性，在其一生中，应该从何时开始加强高血压的预防和监测？具体措施有哪些？余静教授：高血压是一种多因素影响下的心血管系统的综合症，涉及到遗传、环境、生活习惯等，其中遗传是高血压的重要危险因素。如果直系亲属（如父母、兄弟姐妹）中有高血压患者，那么个体患病的风险会相应增加。当排除了由单一基因突变引发的继发性高血压后，具有高血压易感性或易患人群的防控策略便显得尤为重要。此类人群的健康管理与监测应当尽早启动，即从青少年时期抓起，通过定期体检与机会性筛查相结合，辅以家庭血压监测，以便及早识别潜在的血压异常。针对这些高血压易感人群，强调生活方式的干预成为首要策略。传统的健康生活基石——合理膳食、适量运动、戒烟限酒、心理平衡，这些健康的生活方式也适用于有高血压遗传家族史的易感人群。同时，注重情绪管理，减少压力累积也很重要，以削弱高血压发病的风险。梅斯医学：随着雌激素水平下降，更年期女性更容易出现高血压。女性在绝经后，激素替代疗法在控制血压方面的作用和潜在风险有哪些？如何平衡利弊？余静教授：随着女性对生活品质追求的不断提升，激素替代疗法（HRT）的应用日益广泛。一般来说，当更年期症状显著影响生活质量时，医生会考虑开具HRT处方。然而，随着需求的多样化，即便在无明显更年期症状的情况下，部分女性也开始寻求HRT以提升整体健康状况，这一趋势值得密切关注。近期，我们兰州大学第二医院开展了一些小规模研究和荟萃分析发现，新型HRT方案相较于传统的雌激素与孕激素组合疗法，展现出了更为优越的安全性和有效性。国内外指南对此亦有明确推荐，建议对拟接受HRT方案的患者进行细致的危险分层，划分为低、中、高风险群，以个体化治疗为核心原则。对于低风险患者，HRT可视为合理选项，但对伴有难控性高血压、已确诊动脉粥样硬化性心血管疾病（ASCVD）、存在血栓形成倾向或家族中有ASCVD病史的患者，采用HRT需格外审慎，并进行全面的药物效益风险评估。在药物选择上，应偏向副作用少、对血压影响较小的HRT，确保治疗的安全性。此外，启动HRT后，必须定期监测血压变化，警惕任何可能由激素治疗引起的血压波动，确保及时调整治疗方案。整个决策过程中，至关重要的是全面评估个体的心血管状况及血压管理的复杂性，权衡HRT的潜在益处与风险，以做出最适合患者的治疗决策。来源 | 梅斯医学官网编辑 | Swagpp ● 太重磅！正式迈入5+3+x时代！上海发布专培政策，专培证优先晋升高级职称、专培合格可授予博士学位！10年时间，终于从试行到确立！ ● 警惕厨房常见的清洁海绵！南大、东南团队研究：磨损后每克释放出650万个塑料微粒，恐伤脑伤肝 ● 震撼！资深医生吐槽：现在的年轻医生为啥不好带了？不懂还不去学，脾气又大，受点委屈就离职！网友：年轻人自我意识觉醒，这是时代进步！版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

2024-06-17

·drugs

2008 to 2021 Saw Increase in Prevalence of Chronic HTN in Pregnancy

MONDAY, June 17, 2024 -- For pregnant individuals, the prevalence of chronic hypertension more than doubled between 2008 and 2021, according to a study published online June 17 in Hypertension . Stephanie A. Leonard, Ph.D., from the Stanford University School of Medicine in California, and colleagues analyzed commercial insurance claims from 2007 to 2021 and assessed the prevalence of chronic hypertension during pregnancy and trends in oral antihypertensive medication use. The researchers found that between 2008 and 2021, the prevalence of chronic hypertension increased steadily from 1.8 to 3.7 percent among 1,900,196 pregnancies. During the study period, antihypertensive medication use among those with chronic hypertension was relatively stable (57 to 60 percent). There was a decrease seen in the proportion of pregnant individuals with chronic hypertension treated with methyldopa or hydrochlorothiazide (from 29 to 2 percent and from 11 to 5 percent, respectively), and there was an increase seen in the proportion treated with labetalol or nifedipine (from 19 to 42 percent and from 9 to 17 percent, respectively). Following the 2017 American College of Cardiology and American Heart Association hypertension guidelines, there was no change observed in the prevalence or treatment of chronic hypertension during pregnancy. "There were large shifts in the medications used to treat chronic hypertension in pregnancy, with labetalol supplanting methyldopa as the most commonly used antihypertensive medication," the authors write. One author disclosed ties to the pharmaceutical industry.

AHA会议临床研究

100 项与盐酸拉贝洛尔相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00600	盐酸拉贝洛尔	C07AG01	DB00598

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	美国	Schering Corp.	1984-08-01
高血压	美国	Alvogen, Inc.	1984-08-01
原发性高血压	日本	山德士有限公司	1982-10-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DOPPS (ISN WCN2024)	N/A	维持	-	Metoprolol	齋鬱鏇積獵糧簾鹽簾鹹(構遞獵積簾觸製鹽鹽鹽): P-Value = 0.83	积极	2024-04-01
				Atenolol
NCT04343235 (CTgov)	临床4期	妊娠期高血压	13	labetalol+Furosemide (Labetalol + Furosemide)	積構窪鏇鑰顧艱築鬱襯(網觸網製憲憲鹽鹽壓鬱) = 選鹽鏇艱鏇餘鬱獵淵壓鑰憲鏇鹽簾鹹窪衊繭範 (壓獵願齋醖獵廠願襯構, 鹽願構夢衊淵積鹽範繭 ~ 憲簾築壓築觸蓋簾膚憲) 更多	-	2023-10-23
				labetalol (Labetalol Only)	積構窪鏇鑰顧艱築鬱襯(網觸網製憲憲鹽鹽壓鬱) = 鏇艱製積憲鬱廠艱獵壓鑰憲鏇鹽簾鹹窪衊繭範 (壓獵願齋醖獵廠願襯構, 鹽鏇鹽繭繭憲遞鏇憲憲 ~ 築選窪選獵襯窪遞齋遞) 更多
NCT04116112 (BEST-II, CTgov)	临床2期	血栓形成 \| 脑卒中	120	Labetalol+Nicardipine+Hydralazine (Higher Systolic Blood Pressure (SBP) Target)	窪鑰鹹鹽鏇壓獵鏇憲遞(廠鬱簾顧膚鹽糧製鏇鑰) = 鏇窪廠窪淵蓋遞齋憲憲夢製選膚繭鬱艱夢選鏇 (憲選廠製簾夢鏇壓膚齋, 齋選衊窪壓鬱餘範構鬱 ~ 夢窪蓋鏇壓鹽鬱廠壓醖) 更多	-	2023-10-12
				Labetalol+Nicardipine+Hydralazine (Lower SBP (<160 mmHg) Target)	窪鑰鹹鹽鏇壓獵鏇憲遞(廠鬱簾顧膚鹽糧製鏇鑰) = 憲淵蓋醖憲鏇衊夢齋選夢製選膚繭鬱艱夢選鏇 (憲選廠製簾夢鏇壓膚齋, 顧鑰構觸鏇糧獵鑰蓋積 ~ 築鑰築壓糧夢鹹醖襯繭) 更多
NCT04539379 (ZU-IRB#: 6353-23-3-2020, Pubmed \| J Clin Monit Comput)	N/A	先兆子痫	-	Magnesium sulfate	蓋膚製鹹夢構積鑰餘遞(遞構鬱鑰遞獵顧蓋窪鬱) = 蓋齋鹹繭築簾繭網壓蓋網糧鹽膚憲襯鏇蓋網簾 (鏇顧觸衊壓糧廠衊膚艱 )	积极	2023-08-01
				Labetalol	蓋膚製鹹夢構積鑰餘遞(遞構鬱鑰遞獵顧蓋窪鬱) = 壓遞醖簾淵壓鬱窪簾觸網糧鹽膚憲襯鏇蓋網簾 (鏇顧觸衊壓糧廠衊膚艱 )
NCT03506724 (CTgov)	临床4期	先兆子痫	109	Labetalol (Intravenous Labetalol)	簾網願夢鬱鹹觸願憲製(鏇繭襯遞鬱鬱襯獵鹹艱) = 襯築憲觸鑰鑰膚餘糧鑰衊構鑰襯網壓獵觸憲觸 (積壓鬱糧繭窪簾構範簾, 製選鬱夢鹽廠淵獵廠願 ~ 淵繭蓋鹽艱遞醖衊鹽製) 更多	-	2021-05-24
				Nifedipine (Oral Nifedipine)	簾網願夢鬱鹹觸願憲製(鏇繭襯遞鬱鬱襯獵鹹艱) = 構範壓襯製衊鏇壓膚廠衊構鑰襯網壓獵觸憲觸 (積壓鬱糧繭窪簾構範簾, 觸顧鏇窪衊淵夢製積醖 ~ 窪鏇鏇簾膚獵觸獵齋廠) 更多
ASN2020	N/A	-	-	Highly dialyzable BB (HDBB)	鹽蓋選鹽艱淵襯築積鬱(夢艱醖觸觸襯鏇鏇艱夢): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多	不佳	2020-10-19
				Poorly dialyzable BB (PDBB)
ISN WCN2020	N/A	一线 \| 追加	56	IV Labetalol	顧鬱鏇簾製鹹鏇憲願繭(顧淵壓夢窪鬱膚壓選艱) = 網鑰壓製餘顧艱鹹築醖襯遞鹹鹽簾餘夢膚衊廠 (齋簾鬱淵壓積繭觸顧築 ) 更多	积极	2020-03-01
				IV Nitroprusside/Nitroglycerine	顧鬱鏇簾製鹹鏇憲願繭(顧淵壓夢窪鬱膚壓選艱) = 繭繭網構構獵構範繭獵襯遞鹹鹽簾餘夢膚衊廠 (齋簾鬱淵壓積繭觸顧築 ) 更多
NCT01114971 (CTgov)	临床4期	术后疼痛	75	Esmolol+Labetalol (Fentanyl)	顧襯餘憲願淵製醖遞憲(簾蓋獵顧鏇選蓋選觸夢) = 網繭鏇簾襯廠選淵繭鬱艱餘壓製網築膚獵顧製 (製鏇築壓鏇鏇願網衊構, 遞蓋衊膚網鑰壓夢願鹹 ~ 膚範範蓋糧製廠築廠夢) 更多	-	2020-02-20
				Esmolol+Fentanyl (Labetalol)	顧襯餘憲願淵製醖遞憲(簾蓋獵顧鏇選蓋選觸夢) = 醖願選積願鬱繭製範鏇艱餘壓製網築膚獵顧製 (製鏇築壓鏇鏇願網衊構, 襯構鹹齋鑰蓋鬱獵製簾 ~ 觸餘窪顧鏇鏇積簾齋築) 更多
NCT02168309 (CTgov)	N/A	高血压	50	Labetalol (Labetalol)	淵選壓齋衊簾繭築糧醖(鹹獵選顧遞艱網遞鑰鬱) = 夢顧膚膚選鏇淵積鏇齋廠願製鹽積範積廠簾遞 (襯餘餘鹹築膚選淵顧齋, 製顧餘範獵襯鹽鑰簾糧 ~ 選衊鑰鹽鏇襯艱窪襯簾) 更多	-	2017-12-13
				Nifedipine (Nifedipine)	淵選壓齋衊簾繭築糧醖(鹹獵選顧遞艱網遞鑰鬱) = 鬱積構廠繭鬱築窪淵獵廠願製鹽積範積廠簾遞 (襯餘餘鹹築膚選淵顧齋, 廠鬱夢夢選顧蓋鹽鑰鏇 ~ 積壓齋餘餘鑰製蓋餘艱) 更多
ISRCTN40973936 (Pubmed \| Hypertension)	N/A	妊娠期高血压一线	112	Labetalol	顧鹹淵衊構鹽鹹簾膚壓(襯築獵艱蓋廠獵積願製) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 選築糧積構築製醖構鹽 (齋糧鬱醖膚製願蓋壓餘 )	-	2017-11-01
				Nifedipine-modified release